Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Latest Information Update: 14 Jul 2025
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Acronyms ENLIGHT
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 03 Jul 2025 Status changed from active, no longer recruiting to completed.
- 08 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2023 Status changed from not yet recruiting to recruiting.